Vistagen Therapeutics Reports 2026 Annual Meeting Results, Directors Re‑Elected

What Happened Vistagen Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders held on September 10, 2026 (Form 8‑K filed Sept 11, 2026). Shareholders elected all four director nominees to the board, approved the advisory (non‑binding) vote on executive compensation, and ratified KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending March 31, 2027.

Key Details

• Board elections: all four nominees elected to serve until the 2027 Annual Meeting.
  • Jon S. Saxe: For 7,354,923; Withheld 1,141,965
  • Ann M. Cunningham: For 4,664,450; Withheld 3,832,438
  • Douglas J. Williamson: For 7,382,907; Withheld 1,113,981
  • Shawn K. Singh (President & CEO): For 4,971,180; Withheld 3,525,708
• Say‑on‑pay (advisory approval of named executive officer compensation): For 6,625,045; Against 1,142,430; Abstain 729,413 — proposal approved.
• Auditor ratification: KPMG LLP ratified as independent registered public accounting firm for FY ending March 31, 2027 — For 22,495,649; Against 680,897; Abstain 685,683.
• Reference: the company’s definitive proxy statement was filed with the SEC on July 31, 2026.

Why It Matters These outcomes confirm shareholder support for Vistagen’s current board composition and executive pay practices and establish KPMG as the auditor for the upcoming fiscal year. For investors, re‑election of directors and an approved say‑on‑pay vote signal continuity in governance and management strategy; ratification of KPMG ensures the company’s financial statements for FY 2027 will be audited by that firm.